

CME/CE-Certified myCME Go Mobile Webcast

Chronic Idiopathic Constipation: Therapeutic Options — Issue 3

FACULTY PRESENTER

Brian E. Lacy, PhD, MD, FACG Senior Associate Consultant Mayo Clinic Jacksonville, FL

CONTENT REVIEWERS

Thomas A. Ullman, MD

Professor of Gastroenterology Chief, Division of Gastroenterology Department of Medicine Albert Einstein College of Medicine Montefiore Medical Center Bronx, NY

Victor B. Hatcher, PhD

Associate Dean and Director of CME Professor of Medicine and Biochemistry Albert Einstein College of Medicine Montefiore Medical Center Bronx, NY

Dorothy Duffy, RPh, BS Pharmacy

Pharmacist Van Houten Pharmacy Clifton, NJ

PROGRAM DESCRIPTION

Although chronic idiopathic constipation (CIC, also known as functional constipation) is common, it is not inconsequential. It can carry a heavy sociomedical burden and have a profound negative impact on quality of life—problems that are compounded by late or inaccurate diagnosis and, all too often, inadequate or inappropriate management. In some cases, patients refrain from complaining about bowel problems out of embarrassment or a sense that they can manage them on their own. In other cases, clinicians fail to proactively ask about bowel symptoms or to listen fully to patients' accounts of nonprescription treatment strategies they have already tried without success. In this podcast, a noted expert illustrates a patient-centric, stepwise approach to care that directs effective treatment to the patient's specific complaints, thus reducing diagnostic delays and improving treatment adherence, thereby enhancing treatment outcomes and patient satisfaction.

INTENDED AUDIENCE

Clinicians who treat individuals with irritable bowel syndrome/chronic idiopathic constipation (IBS/CIC), including gastroenterologists, internal medicine and family physicians, gynecologists, pharmacists, and nurse practioners (NPs) and physician assistants (PAs) who work in gastroenterology, gynecology, or primary care settings

LEARNING OBJECTIVES

After participating in this activity, learners should be better able to:

- Implement individualized treatment plans for patients with chronic idiopathic constipation (CIC) that incorporate data from randomized controlled trials and evidence-based recommendations
- Utilize patient-centric counseling strategies for patients with CIC to support prompt identification of inadequate or poorly tolerated therapy and support long-term therapeutic adherence

ACCREDITATION STATEMENT

Albert Einstein College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AKH Inc., Advancing Knowledge in Healthcare is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

CREDIT DESIGNATION STATEMENT

Albert Einstein College of Medicine designates this enduring material for a maximum of 0.25 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AKH Inc., Advancing Knowledge in Healthcare approves this knowledge-based activity for 0.25 contact hour (0.025 CEU). UAN 0077-9999-19-007-H04-P. Initial release date: 6/14/2019.

If you claim CE for Pharmacy credit, you will be prompted to include your National Association of Boards of Pharmacy (NABP) number and date/month of birth. This information must be included in order for you to receive credit.

PHYSICIAN ASSISTANT CONTINUING EDUCATION

AAPA accepts certificates of participation for educational activities certified for *AMA PRA Category 1 Credit*^m from organizations accredited by ACCME or a recognized state medical society. PAs may receive a maximum of 0.25 Category 1 Credit for completing this activity.

NURSE PRACTITIONER CONTINUING EDUCATION

The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts certificates of participation for education activities certified for *AMA PRA Category 1 Credit™* from organizations accredited by ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.

CONFLICT OF INTEREST DISCLOSURE POLICY

In accordance with the ACCME's Standards for Commercial Support of Continuing Medical Education, all faculty and planning partners must disclose any financial relationship(s) or other relationship(s) held within the past 12 months. Albert Einstein College of Medicine and AKH Inc., Advancing Knowledge in Healthcare implement a mechanism to identify and resolve all conflicts of interest prior to delivering the educational activity to learners.

FACULTY DISCLOSURES

The faculty reported the following financial relationships or relationships to products or devices they have with commercial interests related to the content of this CME/CE activity.

- Brian E. Lacy, PhD, MD, FACG, receives consulting fees from Salix, Ironwood Pharmaceuticals, and Shire.
- **Dorothy Duffy, RPh, BS Pharmacy,** has no relevant financial relationships to disclose.
- Victor B. Hatcher, PhD, has no relevant financial relationships to disclose.
- Thomas A. Ullman, MD, receives consulting fees from Pfizer Inc.

ACCREDITED PROVIDER DISCLOSURE

Albert Einstein College of Medicine; AKH Inc., Advancing Knowledge in Healthcare; and HME staff involved in the planning this activity have no relevant financial relationships to disclose.

OFF-LABEL DISCLOSURE AND DISCLAIMER

This CME/CE activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient's medical condition.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Allergan, Inc.; Albert Einstein College of Medicine; AKH Inc., Advancing Knowledge in Healthcare; or HME. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.